Literature DB >> 2898025

Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study. The Kroc Collaborative Study Group.

.   

Abstract

The progression of retinopathy was reevaluated at two years in 64 of the 68 patients with mild to moderate diabetic retinopathy, originally randomly assigned for an eight-month period either to intensified diabetic control with continuous subcutaneous insulin infusion (CSII) or to unchanged conventional injection treatment. Twenty-three of the 34 patients in the former group and 24 of the 34 in the latter agreed to continue to follow their original treatment assignment for a further 16 months. The others crossed over at the end of the first eight months of the study. During those first eight months, substantial lowering of blood glucose concentration had been achieved in the CSII group, unexpectedly associated with evidence of accelerated progression of retinopathy compared with the conventional injection treatment group. Glycemic separation was maintained at two years between the two groups continuing to receive the assigned treatment; during this time the mean retinopathy level deteriorated with conventional injection treatment and improved with CSII. At two years the degree of retinopathy in the two treatment groups was indistinguishable, with some trend to lesser overall deterioration with CSII. It is concluded that, in diabetics with mild to moderate nonproliferative retinopathy, the acceleration in activity associated with tightened control is not sustained and does not initiate vasoproliferative deterioration in retinopathy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898025     DOI: 10.1001/jama.1988.03410010045032

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  24 in total

1.  Long-term progression of retinopathy after initiation of insulin therapy in Type 2 diabetes: an observational study.

Authors:  C S Arun; R Pandit; R Taylor
Journal:  Diabetologia       Date:  2004-07-28       Impact factor: 10.122

Review 2.  Costs of insulin-dependent diabetes mellitus.

Authors:  T T Simell; H Sintonen; J Hahl; O G Simell
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

Review 3.  [Normoglycemia as a therapy goal in diabetes treatment--concept and realization].

Authors:  E G Siegel
Journal:  Klin Wochenschr       Date:  1990-03-16

Review 4.  Blood glucose control and microvascular complications--what do we do now?

Authors:  K Dahl-Jørgensen; O Brinchmann-Hansen; H J Bangstad; K F Hanssen
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

5.  Inhibition of EGF signaling protects the diabetic retina from insulin-induced vascular leakage.

Authors:  Masahiko Sugimoto; Alecia Cutler; Bailey Shen; Scot E Moss; Sudha K Iyengar; Ronald Klein; Judah Folkman; Bela Anand-Apte
Journal:  Am J Pathol       Date:  2013-07-03       Impact factor: 4.307

6.  The effect of pregnancy on mild diabetic retinopathy.

Authors:  T Hellstedt; R Kaaja; K Teramo; I Immonen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-07       Impact factor: 3.117

7.  Effects of intensive glycemic control in ocular complications in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.

Authors:  Xiaodan Zhang; Jiangpei Zhao; Tongfeng Zhao; Huanliang Liu
Journal:  Endocrine       Date:  2014-10-30       Impact factor: 3.633

Review 8.  A risk-benefit assessment of conventional versus intensive insulin therapy.

Authors:  P Reichard
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

9.  UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.

Authors: 
Journal:  Diabetologia       Date:  1991-12       Impact factor: 10.122

Review 10.  Influence of the degree of control of diabetes on the prevention, postponement and amelioration of late complications.

Authors:  B R Zimmerman
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.